ABSTRACT
AIMS: Type 2 diabetes mellitus (T2DM) can lead to brain dysfunction and a series of neurological complications. Previous research demonstrated that a novel palmitic acid (5-PAHSA) exerts effect on glucose tolerance and chronic inflammation. Autophagy was important in diabetic-related neurodegeneration. The aim of the present study was to investigate whether 5-PAHSA has specific therapeutic effects on neurological dysfunction in diabetics, particularly with regard to autophagy. METHODS: 5-PAHSA was successfully synthesized according to a previously described protocol. We then carried out a series of in vitro and in vivo experiments using PC12 cells under diabetic conditions, and DB/DB mice, respectively. PC12 cells were treated with 5-PAHSA for 24 h, while mice were administered with 5-PAHSA for 30 days. At the end of each experiment, we analyzed glucolipid metabolism, autophagy, apoptosis, oxidative stress, cognition, and a range of inflammatory factors. RESULTS: Although there was no significant improvement in glucose metabolism in mice administered with 5-PAHSA, ox-LDL decreased significantly following the administration of 5-PAHSA in serum of DB/DB mice (p < 0.0001). We also found that the phosphorylation of m-TOR and ULK-1 was suppressed in both PC12 cells and DB/DB mice following the administration of 5-PAHSA (p < 0.05 and p < 0.01), although increased levels of autophagy were only observed in vitro (p < 0.05). Following the administration of 5-PAHSA, the concentration of ROS decreased in PC12 cells and the levels of CRP increased in high-dose group of 5-PAHSA (p < 0.01). There were no significant changes in terms of apoptosis, other inflammatory factors, or cognition in DB/DB mice following the administration of 5-PAHSA. CONCLUSION: We found that 5-PAHSA can enhance autophagy in PC12 cells under diabetic conditions. Our data demonstrated that 5-PAHSA inhibits phosphorylation of the m-TOR-ULK1 pathway and suppressed oxidative stress in PC12 cells, and exerted influence on lipid metabolism in DB/DB mice.
Subject(s)
Autophagy-Related Protein-1 Homolog/antagonists & inhibitors , Autophagy/drug effects , Neuroprotective Agents/pharmacology , Palmitic Acid/pharmacology , Stearic Acids/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Animals , Autophagy/physiology , Autophagy-Related Protein-1 Homolog/metabolism , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Male , Mice , Mice, Inbred C57BL , Neuroprotective Agents/therapeutic use , PC12 Cells , Palmitic Acid/therapeutic use , Phosphorylation/drug effects , Phosphorylation/physiology , Rats , Signal Transduction/drug effects , Signal Transduction/physiology , Stearic Acids/therapeutic use , TOR Serine-Threonine Kinases/metabolismABSTRACT
Diabetes mellitus (DM) is currently a major global health problem, which is associated with the development of cognitive dysfunction. However, although numerous clinical drugs for hyperglycemia have been used at present, safer and more effective therapeutic intervention strategies for diabetic cognitive impairments are still a huge challenge. Recently, several studies have indicated that a novel class of branched palmitic acid esters of hydroxyl stearic acids (PAHSAs) may have anti-diabetes and anti-inflammatory effects in insulin-resistant mice. Herein, whether the 9-PAHSA that one of the PAHSAs can attenuates DM-associated cognitive impairment in a mouse model of type 2 diabetes has been investigated. Our results showed that 9-PAHSA mildly prevented deficits of spatial working memory in Y-maze test while reversed the preference bias toward novel mice in Social choice test. Furthermore, the effect of REST on cognitive impairment of diabetes was explored for the first time. It was found that the expression of REST in diabetic mice increased, and the expression of target protein BDNF (Brain-derived neurotrophic factor) was decreased. After administration of 9-PAHSA, the situation was reversed. In summary, we conclude that exogenous supplement of 9-PAHSA can improve DM-related cognitive impairment to some extent, and the protective effect may be associated with decreased REST/NRSF (repressor element-1 silencing transcription factor/neuron-restrictive silence factor) and upregulated BDNF expression in frontal cortex.
Subject(s)
Cognitive Dysfunction/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/physiopathology , Palmitic Acid/therapeutic use , Stearic Acids/therapeutic use , Aging/blood , Aging/pathology , Animals , Behavior, Animal , Blood Glucose/metabolism , Body Weight , Brain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Cognitive Dysfunction/blood , Diabetes Mellitus, Experimental/blood , Exploratory Behavior , Male , Memory Disorders/blood , Memory Disorders/complications , Memory Disorders/physiopathology , Mice , Repressor Proteins/metabolism , Social Behavior , Spatial MemoryABSTRACT
Optimizing dietary macronutrients benefits the prevention and management of many human diseases but there is conflicting dietary advice for Parkinson's disease (PD), and no single strategy is universally recommended. Recently, it was shown that dietary stearic acid (C18:0) improves survival and mitochondrial functions in the parkin null Drosophila model of PD. Here, we incorporate stearic acid into high protein and high carbohydrate diets and study survival, climbing ability, mitochondrial membrane potential, respiration, basal reactive oxygen species, and conduct lipidomics assays. We observed that parkin null flies showed improvement in all assays tested when stearic acid was added to the high protein diet but not to the high carbohydrate diet. When lipid proportion was examined, we observed higher levels in flies fed the high protein diet with stearic acid diet and the high carbohydrate diet. Unexpectedly, free levels of fatty acids exhibited opposite trend. Combined, these data suggest that dietary Protein: Carbohydrate ratio and stearic acid influences levels of bound fatty acids. The mechanisms that influence free and bound fatty-acid levels remain to be explored, but one possible explanation is that breakdown products can bind to membranes and improve the mitochondrial functions of parkin null flies.
Subject(s)
Diet , Dietary Supplements , Mitochondria/physiology , Motor Activity/physiology , Parkinson Disease/therapy , Stearic Acids/therapeutic use , Animals , Dietary Carbohydrates , Dietary Proteins , Disease Models, Animal , Drosophila melanogaster , Parkinson Disease/physiopathology , Ubiquitin-Protein LigasesABSTRACT
BACKGROUND: Pressure ulcers, also known as bed sores, pressure sores or decubitus ulcers develop as a result of a localised injury to the skin or underlying tissue, or both. The ulcers usually arise over a bony prominence, and are recognised as a common medical problem affecting people confined to a bed or wheelchair for long periods of time. Anabolic steroids are used as off-label drugs (drugs which are used without regulatory approval) and have been used as adjuvants to usual treatment with dressings, debridement, nutritional supplements, systemic antibiotics and antiseptics, which are considered to be supportive in healing of pressure ulcers. Anabolic steroids are considered because of their ability to stimulate protein synthesis and build muscle mass. Comprehensive evidence is required to facilitate decision making, regarding the benefits and harms of using anabolic steroids. OBJECTIVES: To assess the effects of anabolic steroids for treating pressure ulcers. SEARCH METHODS: In March 2017 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. SELECTION CRITERIA: Published or unpublished randomised controlled trials (RCTs) comparing the effects of anabolic steroids with alternative treatments or different types of anabolic steroids in the treatment of pressure ulcers. DATA COLLECTION AND ANALYSIS: Two review authors independently carried out study selection, data extraction and risk of bias assessment. MAIN RESULTS: The review contains only one trial with a total of 212 participants, all with spinal cord injury and open pressure ulcers classed as stage III and IV. The participants were mainly male (98.2%, 106/108) with a mean age of 58.4 (standard deviation 10.4) years in the oxandrolone group and were all male (100%, 104/104) with a mean age of 57.3 (standard deviation 11.6) years in the placebo group. This trial compared oxandrolone (20 mg/day, administered orally) with a dose of placebo (an inactive substance consisting of 98% starch and 2% magnesium stearate) and reported data on complete healing of ulcers and adverse events. There was very low-certainty evidence on the relative effect of oxandrolone on complete ulcer healing at the end of a 24-week treatment period (risk ratio RR) 0.81, 95% confidence interval (CI) 0.52 to 1.26) (downgraded twice for imprecision due to an extremely wide 95% CI, which spanned both benefit and harm, and once for indirectness, as the participants were mostly male spinal cord injury patients). Thus, we are uncertain whether oxandrolone improves or reduces the complete healing of pressure ulcers, as we assessed the certainty of the evidence as very low.There was low-certainty evidence on the risk of non-serious adverse events reported in participants treated with oxandrolone compared with placebo (RR 3.85, 95% CI 1.12 to 13.26) (downgraded once for imprecision and once for indirectness, as the participants were mostly male spinal cord injury patients). Thus, the treatment with oxandrolone may increase the risk of non-serious adverse events reported in participants.There was very low-certainty evidence on the risk of serious adverse events reported in participants treated with oxandrolone compared with placebo (RR 0.54, 95% CI 0.25 to 1.17) (downgraded twice for imprecision due to an extremely wide 95% CI, which spanned both benefit and harm, and once for indirectness, as the participants were mostly male spinal cord injury patients). Of the five serious adverse events reported in the oxandrolone-treated group, none were classed by the trial teams as being related to treatment. We are uncertain whether oxandrolone increases or decreases the risk of serious adverse events as we assessed the certainty of the evidence as very low.Secondary outcomes such as pain, length of hospital stay, change in wound size or wound surface area, incidence of different type of infection, cost of treatment and quality of life were not reported in the included trial.Overall the evidence in this study was of very low quality (downgraded for imprecision and indirectness). This trial stopped early when the futility analysis (interim analysis) in the opinion of the study authors showed that oxandrolone had no benefit over placebo for improving ulcer healing. AUTHORS' CONCLUSIONS: There is no high quality evidence to support the use of anabolic steroids in treating pressure ulcers.Further well-designed, multicenter trials, at low risk of bias, are necessary to assess the effect of anabolic steroids on treating pressure ulcers, but careful consideration of the current trial and its early termination are required when planning future research.
Subject(s)
Oxandrolone/therapeutic use , Pressure Ulcer/drug therapy , Testosterone Congeners/therapeutic use , Female , Humans , Male , Middle Aged , Off-Label Use , Oxandrolone/adverse effects , Starch/therapeutic use , Stearic Acids/therapeutic use , Testosterone Congeners/adverse effects , Wound HealingABSTRACT
The position of the fatty acids (sn-1, sn-2 and sn-3) (stereospecific numbering (sn)) in triacylglycerol (TAG) molecules produces a characteristic stereospecificity that defines the physical properties of the fats and influences their absorption, metabolism and uptake into tissues. Fat interesterification is a process that implies a positional distribution of fatty acids (FAs) within the TAG molecules, generating new TAG species, without affecting the FA cis-trans natural balance. The interesterified (IE) fats, frequently used in the food industry comprise fats that are rich in long-chain saturated FAs, such as palmitic acid (16:0) and stearic acid (18:0). Within the interesterified fats, a critical role is played by FA occupying the sn-2 position; in fact, the presence of an unsaturated FA in this specific position influences early metabolic processing and postprandial clearance that in turn could induce atherogenesis and thrombogenesis events. Here, we provide an overview on the role of TAG structures and interesterified palmitic and stearic acid-rich fats on fasting and postprandial lipemia, focusing our attention on their physical properties and their effects on human health.
Subject(s)
Dietary Fats/therapeutic use , Fatty Acids/chemistry , Hyperlipidemias/diet therapy , Plant Oils/chemistry , Fatty Acids/therapeutic use , Humans , Hyperlipidemias/metabolism , Palmitic Acid/chemistry , Palmitic Acid/therapeutic use , Plant Oils/therapeutic use , Stearic Acids/chemistry , Stearic Acids/therapeutic use , Stereoisomerism , Triglycerides/chemistry , Triglycerides/therapeutic useABSTRACT
BACKGROUND: The Jatropha curcas plant or locally known as "Pokok Jarak" has been widely used in traditional medical applications. This plant is used to treat various conditions such as arthritis, gout, jaundice, wound and inflammation. However, the nature of compounds involved has not been well documented. Hence, this study was conducted to investigate the anti-inflammatory activity of different parts of J. curcas plant and to identify the active compounds involved. METHODS: In this study, methanol (80%) extraction of four different parts (leaves, fruits, stem and root) of J. curcas plant was carried out. Phenolic content of each part was determined by using Folin-Ciocalteau reagent. Gallic acid was used as the phenol standard. Each plant part was screened for anti-inflammatory activity using cultured macrophage RAW 264.7 cells. The active plant part was then partitioned with hexane, chloroform, ethyl acetate and water. Each partition was again screened for anti-inflammatory activity. The active partition was then fractionated using an open column chromatography system. Single spots isolated from column chromatography were assayed for anti-inflammatory and cytotoxicity activities. Spots that showed activity were subjected to gas chromatography mass spectrophotometry (GC-MS) analysis for identification of active metabolites. RESULTS: The hexane partition from root extract showed the highest anti-inflammatory activity. However, it also showed high cytotoxicity towards RAW 264.7 cells at 1 mg/mL. Fractionation process using column chromatography showed five spots. Two spots labeled as H-4 and H-5 possessed anti-inflammatory activity, without cytotoxicity activity. Analysis of both spots by GC-MS showed the presence of hexadecanoic acid methyl ester, octadecanoic acid methyl ester and octadecanoic acid. CONCLUSION: This finding suggests that hexadecanoic acid methyl ester, octadecanoic acid methyl ester and octadecanoic acid could be responsible for the anti-inflammatory activity of the J. curcas root extract.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammation/drug therapy , Jatropha/chemistry , Macrophages/drug effects , Palmitic Acid/pharmacology , Plant Extracts/pharmacology , Stearic Acids/pharmacology , Animals , Anti-Inflammatory Agents/analysis , Anti-Inflammatory Agents/therapeutic use , Mice , Molybdenum , Palmitic Acid/analysis , Palmitic Acid/therapeutic use , Phenols/analysis , Phenols/pharmacology , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Plant Roots/chemistry , Stearic Acids/analysis , Stearic Acids/therapeutic use , Tungsten CompoundsABSTRACT
The influence of saturated N-acylethanolamine--N-stearoylethanolamine (NSE) on the activity of angiotensine-converting enzyme (ACE) in the brain structures of rats with streptozotocine-induced diabetes was studied. It was shown that decreased activity of ACE was observed in the hypothalamus, increased--in the anterior pituitary. The NSE suspension administration to rats with experimental diabetes in a dose 50 mg/kg of body weight during 10 days caused a decrease in ACE activity in the anterior pituitary, whereas in the hypothalamus and hippocampus ACE activity did not change significantly. At the same time, introduction of NSE to intact animals led to the reduction of activity of ACE in the hippocampus, anterior pituitary and blood plasma. It is known that the highest amount of ACE in the brain structures is located in the membrane-bound state. Thus, the changes we have found in the activity of ACE in the control rats and in animals with induced diabetes may be related to the ability of NSE to the modulation of cell membranes lipid profile. Changes in the activity of ACE under the action of N-acylethanolamines may be one of the mechanisms for implementation of anti-hypertensive and anti-inflammatory action of these compounds.
Subject(s)
Antihypertensive Agents/administration & dosage , Diabetes Mellitus, Experimental/drug therapy , Ethanolamines/administration & dosage , Hypertension, Renal/drug therapy , Peptidyl-Dipeptidase A/metabolism , Stearic Acids/administration & dosage , Administration, Oral , Animals , Antihypertensive Agents/therapeutic use , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/enzymology , Ethanolamines/therapeutic use , Hippocampus/drug effects , Hippocampus/metabolism , Hypertension, Renal/complications , Hypertension, Renal/enzymology , Hypothalamus/drug effects , Hypothalamus/metabolism , Male , Pituitary Gland, Anterior/drug effects , Pituitary Gland, Anterior/metabolism , Rats , Renin-Angiotensin System/drug effects , Stearic Acids/therapeutic useABSTRACT
A functional oil containing diacylglycerol (DAG) and monoacylglycerol (MAG) has been shown to have a strong anti-atherosclerotic effect in a mouse model. Among the lipid components, MAG is responsible for the beneficial effect with an enhanced antioxidant effect in the mouse model. In this report, several MAG-containing fatty acids (MAG-oleic acid [MAG-O], MAG-palmitic acid [MAG-P], and MAG-stearic acid [MAG-S]) were synthesized, and the antioxidant and anti-atherogenic activities were evaluated in vitro and in a cellular model. MAG-O had the strongest radical scavenging and antioxidant activities against copper-mediated low-density lipoprotein (LDL) oxidation and the strongest inhibitory activity against LDL-associated phospholipase A(2) and exhibited potent activation of paraoxonase activity, which contributes to the maintenance of antioxidant activity. All MAG species in this study exhibited inhibitory activity against glycation of apolipoproteins, in contrast to DAG. Oxidized LDL uptake into THP-1 cells was strongly inhibited by MAG-O treatment at a final concentration of 20 microM. MAG-O-treated cell culture medium showed the lowest production of malondialdehyde and lipid hydroperoxide compared to MAG-S and MAG-P. In conclusion, MAG-O had potent antioxidant, antidiabetic, and anti-atherogenic effects in vitro and in a cellular model.
Subject(s)
Antioxidants/pharmacology , Apolipoproteins/metabolism , Atherosclerosis/prevention & control , Dietary Fats/pharmacology , Fatty Acids/pharmacology , Lipid Peroxidation/drug effects , Monoglycerides/pharmacology , Aryldialkylphosphatase/metabolism , Cell Line , Cholesterol, LDL/metabolism , Fatty Acids/therapeutic use , Functional Food , Glycosylation , Humans , Lipid Peroxides/metabolism , Male , Malondialdehyde/metabolism , Monoglycerides/therapeutic use , Oleic Acid/pharmacology , Oleic Acid/therapeutic use , Palmitic Acid/pharmacology , Palmitic Acid/therapeutic use , Phospholipases A2/metabolism , Stearic Acids/pharmacology , Stearic Acids/therapeutic useABSTRACT
There are multiple adverse effects of trans fatty acids (TFA) that are produced by partial hydrogenation (i.e., manufactured TFA), on CVD, blood lipids, inflammation, oxidative stress, endothelial health, body weight, insulin sensitivity, and cancer. It is not yet clear how specific TFA isomers vary in their biological activity and mechanisms of action. There is evidence of health benefits on some of the endpoints that have been studied for some animal TFA isomers, such as conjugated linoleic acid; however, these are not a major TFA source in the diet. Future research will bring clarity to our understanding of the biological effects of the individual TFA isomers. At this point, it is not possible to plan diets that emphasize individual TFA from animal sources at levels that would be expected to have significant health effects. Due to the multiple adverse effects of manufactured TFA, numerous agencies and governing bodies recommend limiting TFA in the diet and reducing TFA in the food supply. These initiatives and regulations, along with potential TFA alternatives, are presented herein.
Subject(s)
Trans Fatty Acids/adverse effects , Trans Fatty Acids/chemistry , Cardiovascular Diseases/etiology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/prevention & control , Endothelium, Vascular/metabolism , Food Industry , Food Labeling , Humans , Isomerism , Stearic Acids/metabolism , Stearic Acids/therapeutic use , Trans Fatty Acids/administration & dosageABSTRACT
Earlier, we reported that oils rich in omega-3 eicosapentaenoic acid and docosahexaenoic acid and omega-6 gamma-linolenic acid and arachidonic acid prevented the development of alloxan-induced diabetes mellitus in experimental animals. Here we report the results of our studies with pure saturated stearic acid (SA), monounsaturated oleic acid (OA) and omega-6 arachidonic acid (AA) on alloxan-induced diabetes mellitus in Wistar male rats. Prior oral supplementation with AA prevented alloxan-induced diabetes mellitus, whereas both SA and OA were ineffective. Cyclo-oxygenase (COX) and lipoxygenase (LO) inhibitors did not block this protective action of AA against alloxan-induced diabetes, suggesting that both prostaglandins and leukotrienes are not involved, and that AA by itself is effective. Furthermore, AA restored the anti-oxidant status to normal range in various tissues. These results suggest that AA protects pancreatic beta cells against alloxan-induced diabetes in experimental animals by attenuating oxidant stress.
Subject(s)
Arachidonic Acid/pharmacology , Diabetes Mellitus, Experimental/prevention & control , Oleic Acid/pharmacology , Stearic Acids/pharmacology , Alloxan , Animals , Arachidonic Acid/blood , Arachidonic Acid/therapeutic use , Blood Glucose/metabolism , Body Weight/drug effects , Catalase/metabolism , Ceruloplasmin/metabolism , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 1/chemically induced , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/prevention & control , Erythrocytes/drug effects , Erythrocytes/enzymology , Erythrocytes/metabolism , Glutathione Peroxidase/metabolism , Glutathione Transferase/metabolism , Indomethacin/pharmacology , Insulin/blood , Kidney/drug effects , Kidney/enzymology , Kidney/metabolism , Lactic Acid/blood , Lipid Peroxides/blood , Lipid Peroxides/metabolism , Liver/drug effects , Liver/enzymology , Liver/metabolism , Male , Malondialdehyde/blood , Malondialdehyde/metabolism , Masoprocol/pharmacology , Nitric Oxide/blood , Nitric Oxide/metabolism , Oleic Acid/blood , Oleic Acid/therapeutic use , Pancreas/drug effects , Pancreas/enzymology , Pancreas/metabolism , Phospholipids/chemistry , Rats , Rats, Wistar , Stearic Acids/blood , Stearic Acids/therapeutic use , Superoxide Dismutase/metabolismSubject(s)
Glycyrrhiza , Hydroxy Acids/isolation & purification , Oleic Acids/isolation & purification , Plants, Medicinal , Stearic Acids/isolation & purification , Stress, Physiological/drug therapy , Adrenalectomy , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Gas Chromatography-Mass Spectrometry , Hydroxy Acids/analysis , Hydroxy Acids/therapeutic use , Mice , Oleic Acids/analysis , Oleic Acids/therapeutic use , Rats , Stearic Acids/analysis , Stearic Acids/therapeutic useABSTRACT
Two cases of unresectable intra-cranial arterio-venous malformation (AVM) are reported, treated by direct intra-operative embolization. A 50% mixture of Butyl-2-Cyano-Acrylate and Mono-Iodo-Stearate of Ethyle (Duroliopaque) was used after catheterization of some of the feeding cortical arteries. No intra-operative angiography was performed. The first patient, admitted after subarachnoid hemorrhage and presenting with a mild transient right hemiparesia and aphasia, showed evidence of a left temporal AVM with a left middle cerebral artery supply and contribution from the left cerebral posterior artery. The AVM was embolized with 3 cc of the mixture. A mild aphasia occurred after surgery and completely recovered after two weeks. Roughly half of the AVM was occluded on the postoperative angiograms. The second patient suffering from a long history of seizures had a huge right frontal AVM, with a right middle cerebral artery and right anterior cerebral artery supply, and contribution from a right lenticulostriate artery, the left anterior cerebral artery and the right posterior cerebral artery. The AVM was embolized with 7 cc of the mixture. A complete palsy of the left upper limb occurred after surgery, with complete recovery after two weeks. On the post-operative angiograms, more than three fourth of the AVM was occluded.
Subject(s)
Embolization, Therapeutic , Enbucrilate/therapeutic use , Intracranial Arteriovenous Malformations/therapy , Iodized Oil/therapeutic use , Stearates/therapeutic use , Stearic Acids/therapeutic use , Adult , Humans , Intraoperative Period , Male , Middle Aged , Postoperative Period , Time FactorsABSTRACT
Intraperitoneal injection of bromstearate inhibited the oxidation of fatty acids and glyconeogenesis and enhanced the glucose oxidation in intact animals and in rats with diabetes. Bromstearate induced marked hypoglycemia in intact animals, normalized hyperglycemia in rats with alloxan diabetes for 24 hours after the administration. In intact rats daonyl failed to influence fatty acid and glucose oxidation, but induced moderate hypoglycemia. In rats with alloxan diabetes daonyl inhibited oxidation of glucose and, to a lesser extent, of fatty acids, without any changes of hyperglycemia. Inhibitors of fatty acids oxidation are suggested for the pathogenetic therapy of diabetes.
Subject(s)
Antioxidants/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Glyburide/therapeutic use , Hypoglycemic Agents/therapeutic use , Oleic Acids/metabolism , Stearic Acids/therapeutic use , Alloxan , Animals , Drug Evaluation, Preclinical , Male , Oxidation-Reduction/drug effectsABSTRACT
Prophylactic and therapeutic administration of pyrasol derivatives butadion and stampyrine (antipyrilamide of stearic acid), to rats with adjuvant polyarthritis normalize the structure of the synovial membrane, capsule and of the periarticular tissue of the talocrural articulations, stabilize the proteinic-mucopolysaccharide complexes, lower the permeability of the lysosome membranes and vascular walls and inhibit the phagocystic activity of the histiocytes. Both drugs do not lessen the proliferation of the fibroblasts, but normalize the processes of the collagenogenesis them. The prophylactic and therapeutic effects of stampyrine are superior to those of butadion.